Bone Metastatic Castration-Resistant Prostate Cancer Clinical Trial
Official title:
Pharmacodynamic Study of Radium-223 in Men With Bone Metastatic Castration-Resistant Prostate Cancer
This study will examine biomarkers involved in osteomimicry in bone metastases and
circulating tumor cells (CTCs) of men with mCRPC before and during therapy with the
bone-targeting radiopharmaceutical radium-223. This study will also examine the
bio-distribution of radium-223 in bone and bone metastases of men with mCRPC.
The investigators hypothesize that bone metastases and CTCs in men with mCRPC will commonly
express markers of EMT/plasticity and osteomimicry, not just in the normal surrounding
osteoblastic stroma but in the epithelial tumor cells themselves and that radium-223 will
target both of these compartments including the more mesenchymal/osteoblastic tumor cells and
the surrounding osteoblasts in the active bone microenvironment, with a relative sparing of
normal bone and bone marrow.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04521361 -
A Study to Assess How Radium-223 Distributes in the Body of Patients With Prostate Cancer Which Spread to the Bones
|
Phase 1 | |
| Completed |
NCT04587427 -
A Study to Learn More About How Radium-223 is Being Used With Other Treatments in European Patients Who Have Not Received Radium-223 Before
|